Does perimenopause really kill your libido? Here's what the data says

What's this video probably claiming?

Based on the caption and hashtag context, this creator is likely walking through why libido drops during perimenopause and menopause, and nudging viewers toward hormonal solutions, probably including testosterone. The caption cuts off mid-sentence with "It's not just estroge" which is a fairly transparent setup for a testosterone pitch. That framing, combined with the TRT category tag, suggests the video argues that testosterone decline, not just estrogen loss, is responsible for the drop in sexual desire. She's probably right that desire changes are real and physiological, not imaginary or psychological. Whether her explanation of the mechanism holds up to scrutiny is a different question.

What does the science actually show?

The basic premise is well-supported. Estrogen, testosterone, and progesterone all decline during the menopausal transition, and all three influence sexual function through different pathways. Davis et al. (2019, The Lancet Diabetes and Endocrinology) found that low testosterone in women correlates with reduced sexual desire, satisfaction, and frequency of sexual activity. The HSDD (hypoactive sexual desire disorder) literature is reasonably consistent here. But the picture is complicated. Shifren et al. (2008, NEJM) showed that transdermal testosterone at 300 micrograms per day improved satisfying sexual events in surgically menopausal women, but the effect size was modest, roughly 2 additional satisfying sexual events per month versus placebo. Genitourinary syndrome of menopause, driven largely by estrogen loss, also contributes to discomfort that suppresses desire. The brain's reward circuitry, dopaminergic tone, and stress hormones are also in play. Testosterone is part of the story, not the whole story.

Where does the social media noise diverge from clinical reality?

Here is where it gets messy. TikTok content in this space tends to frame testosterone as the missing piece women have been denied by a medical establishment that only cared about men. That framing is emotionally resonant and partly true, but it glosses over real gaps. There is no FDA-approved testosterone product for women in the United States. Clinicians prescribing testosterone off-label for female sexual dysfunction are doing so with weaker long-term safety data than most patients realize. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Traish et al., 2019, Journal of Sexual Medicine) supports short-term use but explicitly notes inadequate data on cardiovascular and breast cancer risk beyond 24 months. Social media creators rarely lead with that caveat. The other divergence is dosing. Women need physiological female-range testosterone levels, not male-range levels. Pellet therapy in particular gets promoted widely online and carries real risks of overdose because pellets cannot be titrated once inserted.

What should you actually know?

If your libido has genuinely tanked during perimenopause or menopause, that deserves a clinical conversation, not a TikTok prescription. Start with a provider who will actually measure your hormone levels including estradiol, free testosterone, SHBG, and TSH before assuming the cause. Thyroid dysfunction mimics low-libido menopause symptoms and is frequently missed. If testosterone therapy is appropriate, transdermal preparations at female-specific doses are the most studied route. Pellets should be approached with caution given the inability to adjust dosing post-insertion. Addressing genitourinary symptoms with local estrogen often improves desire indirectly by reducing painful intercourse. The ISSWSH (International Society for the Study of Women's Sexual Health) published a comprehensive process of care document in 2020 that is worth reading, or at least asking your doctor about. The TikTok conversation around this topic is better than nothing, but it moves fast and skips the nuance that actually matters for safe care.